ConceptChemistry
Clinical trials
Drug studies in humans generally broken down into Phase I, II, and III (and Phase IV after approval), used to test safety and effectiveness.
Know first
Named as a prerequisite by the lectures that define this. The number is how many say so. A grey one has no page yet.
Drug development1FDA regulations1
Opens up
Concepts that name this one as a prerequisite.
Lecturers
1Lectures that assume it
62The first 12 are shown.
- Targeting Drug Tolerant Persister State in Lung Cancer (Yale Cancer Center Grand Rounds)
- Therapeutic Targeting of Epigenetic Mechanisms in Cancer (Yale Cancer Center Grand Rounds)
- Evolutionary Medicine
- Breast Cancer in Young Women: Optimizing Knowledge and Care to Improve Outcomes
- WHO Safe Surgery and Safe Childbirth Checklists
- OPERATIONAL DESIGN CONSIDERATIONS IN RCTS _ DR SHRIKANT I BANGDIWALA
- CRITICAL APPRAISAL OF A RANDOMIZED CONTROL TRIAL _ DR THAMBU DAVID
- PFO Closure Board at University of Louisville by Dr. Michael Haboubi & Dr. Faraaz Rahman
- Alzheimer's Disease Biomarkers by Dr. Alan Lerner, Case Western Reserve Univ SOM Cleveland Med Ctr
- SECONDARY ANALYSIS OF A CLINICAL TRIAL _ DR SHRIKANT BANGDIWALA
- DEFINING THE STUDY OUTCOME _ DR SHRIKANT I BANGDIWALA
- Day 3 (II) - Statistical methods for interim analysis _ Prof. Shrikant I Bangdiwala
Connections
68The lectures that define it or assume it, and the concepts next to it.
Concepts5
Lectures63
- Esomeprazole as an Example of Drug Testing and Usage
- Targeting Drug Tolerant Persister State in Lung Cancer (Yale Cancer Center Grand Rounds)
- Therapeutic Targeting of Epigenetic Mechanisms in Cancer (Yale Cancer Center Grand Rounds)
- Evolutionary Medicine
- Breast Cancer in Young Women: Optimizing Knowledge and Care to Improve Outcomes
- WHO Safe Surgery and Safe Childbirth Checklists
Show 57 moreShow fewer
- OPERATIONAL DESIGN CONSIDERATIONS IN RCTS _ DR SHRIKANT I BANGDIWALA
- CRITICAL APPRAISAL OF A RANDOMIZED CONTROL TRIAL _ DR THAMBU DAVID
- PFO Closure Board at University of Louisville by Dr. Michael Haboubi & Dr. Faraaz Rahman
- Alzheimer's Disease Biomarkers by Dr. Alan Lerner, Case Western Reserve Univ SOM Cleveland Med Ctr
- SECONDARY ANALYSIS OF A CLINICAL TRIAL _ DR SHRIKANT BANGDIWALA
- DEFINING THE STUDY OUTCOME _ DR SHRIKANT I BANGDIWALA
- Day 3 (II) - Statistical methods for interim analysis _ Prof. Shrikant I Bangdiwala
- TYPE OF HYPOTHESIS _ DR SHRIKANT BANGDIWALA
- Road to COVID Vaccines: Past, Present, and Future
- Human Values in Clinical Algorithms, Old and New
- Ethical Framework for Health Research
- Conducting Clinical Trials
- PET/MR Molecular Imaging of Cancer (Yale Cancer Center Grand Rounds)
- Symptom Science and Cancer Survivors: Lessons Learned, Opportunities, and Challenges
- PDE5 Inhibitors Block MDSC Metabolism in Gastric Adenocarcinoma (Yale Cancer Center Grand Rounds)
- TYPES OF ANALYSIS _ DR SHRIKANT BANGDIWALA
- PHASE I AND PHASE II DESIGNS _ DR MAHESH IYER
- CONDITION POWER IN INTERIM ANALYSES OF A CLINICAL TRIAL _ DR. L. JEYASEELAN
- COMMON RCT DESIGNS IN PHASE IIB AND III CLINICAL TRIALS - PART II _ DR. SHRIKANT I. BANGDIWALA
- COMMON RCT DESIGNS IN PHASE IIB AND III CLINICAL TRIALS - PART I _ DR. SHRIKANT I. BANGDIWALA
- Day 4 (III) - Case studies for early stopping: SHEPS _ Prof. Shrikant I Bangdiwala
- Experimental Study Designs
- Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
- Day 5 - Community and environmental and policy trials _ Prof. Shrikant I Bangdiwala
- Day 3 (I) - End-of- study analyses_ Prof. Shrikant I Bangdiwala
- Day 1 (I) - Why do we need clinical trials _ Prof. SI Bangdiwala
- 2016 Bishop Lecture featuring William Dale, MD, PhD
- PFO Closure and LAA Closure: The Difficult Questions
- Epileptic Spasms by Danielle Takacs, MD, Asst. Professor at Baylor COM/ Texas Children’s Hospital.
- “Remyelination in Multiple Sclerosis”
- "Neurogenetics in 2021: A Diagnostic Odyssey Reconsidered by Dylan C. Brock, MD, MA,
- SYSTEMATIC REVIEW _ DR THAMBU DAVID
- INTERIM ANALYSIS IN A CLINICAL TRIAL _ DR SHRIKANT I BANGDIWALA
- Day 4 (V) - Systematic Review and Meta Analysis _ Prof. Thambu David
- Day 4 (IV) - AI, ML and Computer intensive methods in RCTs _ Prof. Shrikant I Bangdiwala
- Day 3 (IV) Crossover trials design and analysis_ Dr.Visalakshi
- Day 3 (III)-Case studies for early stopping: Condition Power in Interim Analyses _Prof. L.Jeyaseelan
- Day 2 (IV) - Study efficacy outcomes_ Prof. Shrikant I Bangdiwala
- Day 2 (II) - Design considerations - Necessary sample size_ Prof. L.Jeyaseelan
- Day 4 (II) - Adaptive Study designs _ Prof. Shrikant I Bangdiwala
- Day 1 (IV) - Types of hypotheses_Prof. SI Bangdiwala
- Day 1 (II) - Introduction to Randomized Controlled Trials_ Ananta Bangdiwala
- RECENT ADVANCES IN TREATMENT OF STAGE I - III LUNG CANCER - DR. ASHISH SINGH - MEDICAL ONCOLOGY
- Emerging Therapies for Cluster Headache by Zarmina Mufti, MD
- Lecanemab & Donanemab in Early Alzheimer’s Disease by Dr. Robert Friedland & Dr. Michael Sowell
- Tardive Dyskinesia Across the Complexity Spectrum: Quality of Life Improvement to Novel Treatments
- PFO Enigma and Strokes by Tamour Khan Tareen, MD PGY-4 Neurology Resident at Univ of Louisville
- Acute Neuromuscular Diseases in the ICU by Zeng Wang, MD, PhD
- Day 2 (I) - Design and Data Considerations _ Ananta Bangdiwala
- 2018 Bishop Lecture featuring Barbara Koenig, PhD
- Day 4 (I) - Who to Include in Analyses _ Prof. L.Jeyaseelan
- RECENT ADVANCES IN TREATMENT OF STAGE I - III LUNG CANCER - DR. ASHISH SINGH, MEDICAL ONCOLOGY
- Review of Tenecteplase for Thrombolysis for Acute Ischemic Stroke
- “Saving Penumbra: A Multi-Dimensional Approach” by PGY-4 Neurology Chief Resident, Dr. Riwaj Bhagat
- Day 2 (III) - Study Conduct _ Kumar Balasubramanian
- Neuroprotective Strategies in Stroke: Current Concepts and Future Directions
- Evolution of Thrombolytics and Thrombectomy